<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221997</url>
  </required_header>
  <id_info>
    <org_study_id>Strawn EV-SoPRANO</org_study_id>
    <secondary_id>R01HD098757</secondary_id>
    <nct_id>NCT04221997</nct_id>
  </id_info>
  <brief_title>Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.</brief_title>
  <acronym>EV-SoPRANO</acronym>
  <official_title>Extracellular Vesicles as Predictors of Antidepressant Outcomes in Pediatric Anxiety (EV-SOPRANO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, acute, randomized, double-blind, placebo-controlled, flexible-dose trial with&#xD;
      the treatment of sertraline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled trial of an evidence-based antidepressant,&#xD;
      sertraline, in youth (N=120) with generalized, separation and/or social anxiety disorders,&#xD;
      seeks to evaluate the predictive value of plasma EV signatures. Patients will be randomized&#xD;
      to sertraline (25-200 mg/day) or placebo (3:1) and total plasma EVs will be collected at&#xD;
      baseline and serially during the course of the 12-week treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>During the acute treatment phase, 90 patients will be randomized to sertraline and 30 patients will be randomized to placebo (3:1).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Clinical Global Impression-Improvement Scale ≤ 2</measure>
    <time_frame>Week 12</time_frame>
    <description>Primary response outcome will be treatment response based on patients having attained a score on the Clinical Global Impression-Improvement Scale ≤ 2 at Week 12 or Last-Observation-Carried-Forward (LOCF).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 patients will be randomized to sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 patient will be randomized to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>30 healthy comparison subjects will be followed over the course of 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline</intervention_name>
    <description>Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Patients with Anxiety :&#xD;
&#xD;
          -  Written, informed assent and consent.&#xD;
&#xD;
          -  Patients, parent/guardian/LAR must be fluent in the English.&#xD;
&#xD;
          -  8-17 years of age, inclusive, at Visit 1, and who have a parent/guardian/LAR.&#xD;
&#xD;
          -  Patients must meet DSM-5 criteria for generalized, social and/or separation anxiety&#xD;
             disorder, confirmed by the MINI-KID with no lifetime history of mania, OCD or&#xD;
             significant history of trauma exposure.&#xD;
&#xD;
          -  PARS score ≥15 at Visits 1 and 2.&#xD;
&#xD;
          -  Caregiver who is willing to consent to be responsible for safety monitoring of the&#xD;
             patient, provide information about the patient's condition, oversee the administration&#xD;
             of the investigational product.&#xD;
&#xD;
          -  No clinically significant abnormalities on physical examination.&#xD;
&#xD;
          -  Negative pregnancy test at Visit 1 in females.&#xD;
&#xD;
          -  Sexually active patients must practice a reliable method of contraception (Section&#xD;
             15.0) that will continue for the duration of the study and within 30 days following&#xD;
             the end of study participation.&#xD;
&#xD;
          -  Reliable methods of contraception are defined below; other forms of contraceptives&#xD;
             (pharmacological and/or non-pharmacological) are not accepted.&#xD;
&#xD;
               -  surgical sterilization&#xD;
&#xD;
               -  oral contraceptives (e.g., estrogen-progestin combination or progestin)&#xD;
&#xD;
               -  transdermally-delivered contraceptives (e.g., Ortho-Evra), depot injections&#xD;
                  (e.g.,&#xD;
&#xD;
               -  Depo-Provera)&#xD;
&#xD;
               -  vaginal contraceptive ring (e.g., NuvaRing), contraceptive implants (e.g.,&#xD;
                  Implanon, Norplant&#xD;
&#xD;
               -  II/Jadelle)&#xD;
&#xD;
               -  an intrauterine device or&#xD;
&#xD;
               -  diaphragm plus condom.&#xD;
&#xD;
        Inclusion Criteria for Healthy Controls:&#xD;
&#xD;
          -  Written, informed assent and consent.&#xD;
&#xD;
          -  Patients, parent/guardian/LAR must be fluent in the English.&#xD;
&#xD;
          -  8 to 17 years of age, inclusive, at Visit 1, and who have a parent/guardian/LAR.&#xD;
&#xD;
          -  No history of any DSM-5 disorders (nicotine use disorder is permitted, history of&#xD;
             adjustment disorder is permitted), confirmed by the MINI-KID.&#xD;
&#xD;
          -  Caregiver who is willing to consent to be responsible for safety monitoring of the&#xD;
             patient, provide information about the patient.&#xD;
&#xD;
          -  No clinically significant abnormalities on physical examination. Negative pregnancy&#xD;
             test at Screening in females.&#xD;
&#xD;
          -  Negative urine drug screen at Screening.&#xD;
&#xD;
          -  No first-degree relatives with an affective, anxiety or psychotic disorder.&#xD;
&#xD;
        Exclusion Criteria for Patients with Anxiety Disorders and Healthy Comparison:&#xD;
&#xD;
          -  Subjects Co-occurring DSM-5 diagnosis mood (except persistent depressive disorder,&#xD;
             unspecified depressive disorder or co- occurring anxiety disorders, provided that the&#xD;
             primary diagnosis is generalized, social and/or separation anxiety disorder(s)),&#xD;
             eating, bipolar, or psychotic disorders.&#xD;
&#xD;
          -  A history of treatment with SSRIs within 12 weeks of Visit 2 (Baseline) or current&#xD;
             pharmacotherapy with CNS effects that require &gt;5 half-lives for discontinuation.&#xD;
&#xD;
          -  A history of major neurological or medical illness or head trauma with loss of&#xD;
             consciousness for ≥5 minutes.&#xD;
&#xD;
          -  Lifetime history of mania, OCD, or significant history of trauma exposure.&#xD;
&#xD;
          -  History of hypersensitivity to sertraline.&#xD;
&#xD;
          -  Lifetime diagnosis of intellectual disability or history of IQ &lt;70.&#xD;
&#xD;
          -  History of alcohol/substance use disorder or any substance abuse within the past 6&#xD;
             months (nicotine dependence is permitted).&#xD;
&#xD;
          -  Current psychotherapy stable for &lt;2 months prior to Visit 2 (Baseline).&#xD;
&#xD;
          -  Females will not be eligible to participate if they are pregnant, breast feeding or&#xD;
             lactating.&#xD;
&#xD;
          -  The subject lives &gt;100 miles from the University of Cincinnati or &gt;90 minutes from the&#xD;
             CU site or is not able to attend the follow-up visits.&#xD;
&#xD;
          -  Patients who are unable to swallow capsules.&#xD;
&#xD;
          -  Is currently considered at risk of suicide in the opinion of the investigator,&#xD;
             represents an inappropriate risk to the participant and/or could confound the&#xD;
             interpretation of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey R Strawn, MD, FAACAP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi K Schroeder, BS</last_name>
    <phone>513-558-4422</phone>
    <email>heysehk@ucmail.uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashley M Specht, BBA</last_name>
    <phone>513-558-2868</phone>
    <email>huckabam@ucmail.uc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Columbia, New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Levine, MD</last_name>
      <phone>646-774-7331</phone>
    </contact>
    <investigator>
      <last_name>Amir Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Specht</last_name>
      <phone>513-558-2868</phone>
      <email>huckabam@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey R Strawn,, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Jeffrey Strawn, MD</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

